Patients with chemorefractory metastatic colorectal cancer derive no overall survival benefit from giving anti-EGFR ...
KTVU FOX 2 San Francisco on MSN
Trump announces deal to cut IVF drug prices in exchange for tariff relief
President Donald Trump on Friday announced a deal with pharmaceutical company Merck and its U.S. subsidiary, EMD Serono, to ...
Government agreement with IVF drug manufacturer drops price in exchange for tariff reductions, expedited FDA approval ...
MedPage Today on MSN
A Hit and a Miss for Liquid Biopsy to Guide Adjuvant Cancer Therapy
Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...
MedPage Today on MSN
Add-On Radioligand Therapy Slows Metastatic Hormone-Sensitive Prostate Cancer
Patients with metastatic hormone-sensitive prostate cancer (mHSPC) lived significantly longer without disease progression ...
As a newly christened manufacturing facility comes online in one part of Ireland, Merck KGaA plans to turn out the lights at ...
EMD Serono also entered an agreement with the U.S. Secretary of Commerce to exclude its pharmaceutical products and ...
Tarlatamab combined with chemoimmunotherapy achieved a 71% objective response rate in ES-SCLC, with a median response duration of 11 months. The safety profile was manageable, with grade 3 or 4 ...
ITM-11 significantly improved PFS and OS compared to everolimus in GEP-NET patients, meeting primary and secondary endpoints. Subgroup analyses showed ITM-11's efficacy across tumor grades and prior ...
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback